Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06063486 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 1, 2026 to Dec 31, 2026v8
  2. 2 versions Re-verified since Aug 7, 2025, no change to tracked fieldsv6-v7
  3. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Apr 1, 2026 to Mar 1, 2026
    • Study completion date: Apr 1, 2027 to Mar 1, 2027
    • Start date changed from estimate of Apr 1, 2024 to Mar 1, 2024
    • Study sites revised (2)
  4. Start date: Nov 20, 2023 to Apr 1, 2024
    • Primary completion date: Nov 20, 2025 to Apr 1, 2026
    • Study completion date: Nov 20, 2026 to Apr 1, 2027
    v4
  5. Start date: Oct 2, 2023 to Nov 20, 2023
    • Primary completion date: Oct 2, 2025 to Nov 20, 2025
    • Study completion date: Oct 2, 2026 to Nov 20, 2026
    v3
  6. Primary endpoints: 2 to 3v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
Trial Details
NCT Number NCT06063486
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Related terms Myelodysplastic Syndromes, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov